This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutAboutBroad CoverageIndicationsEfficacyEfficacyEfficacyLimited Treatment OptionsSafetySafetySafetyDosingDosingAdult DosingPaediatric Dosing
Paediatric Dosing

ZAVICEFTA (ceftazidime/avibactam) provides dosing options to treat paediatric patients aged 3 months to <18 years with consistent dosing across indications1

Dosage in paediatric patients aged 3 months to <18 years with CrCl* >50 mL/min/1.73 m2 (refer to SmPC for full dosing information)†‡§
Scroll left to view table
Age Group Dose of ceftazidime/ avibactam Frequency Infusion time Duration of treatment
6 months to 
<18 years		 50 mg/kg/12.5 mg/kg to a maximum of 2 g/0.5 g Every 8 hours 2 hours cIAI: 5–14 days
cUTI, including pyelonephritis: 5–14 days
HAP/VAP: 7–14 days
LTO: Guided by the severity of the infection, the pathogen(s) and the patient’s clinical and bacteriological progress||
3 months to <6 months** 40 mg/kg/
10 mg/kg		 Every 8 hours 2 hours
CrCl estimated using the Schwartz bedside formula for paediatric patients aged 3 months and older.The dose of ZAVICEFTA in patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses.For the treatment of cIAI and infections due to aerobic Gram-negative organisms in patients with LTO, ZAVICEFTA should be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.Across all indications, ZAVICEFTA should be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.The total treatment duration shown may include IV ZAVICEFTA followed by appropriate oral therapy.There is very limited experience with the use of ZAVICEFTA for more than 14 days.There is limited experience with the use of ZAVICEFTA in paediatric patients aged 3 months to <6 months. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only.Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion)

Abbreviations:cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; LTO, limited treatment options; SmPC, Summary of Product Characteristics; VAP, ventilator-associated pneumonia.References:ZAVICEFTA. Summary of Product Characteristics, 2022. Dosing

Legal Category: S1A

Further information available upon request
PP-ZVA-IRL-0242. December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.